Premium
Tyrosine hydroxylase deficiency unresponsive to L‐dopa treatment with unusual clinical and biochemical presentation
Author(s) -
De Lonlay P.,
Nassogne M. C.,
Gennip A. H.,
Cruchten A. C.,
Billette de Villemeur T.,
Cretz M.,
Stoll C.,
Launay J. M.,
SteenbergerSpante G. C. V.,
Heuvel L. P. W.,
Wevers R. A.,
Saudubray J. M.,
Abeling N. G. G. M.
Publication year - 2000
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1023/a:1026760602577
Subject(s) - dystonia , tyrosine hydroxylase , dopamine , medicine , endocrinology , mutation , levodopa , disease , biology , parkinson's disease , genetics , gene , psychiatry
Tyrosine hydroxylase (TH) deficiency is generally considered as a cause of the autosomal recessive form of dopa‐responsive dystonia, also known as Segawa disease. Clinical hallmarks comprise parkinsonian and other extrapyramidal symptoms. Biochemically the defect leads to the defective synthesis of catecholamines, in particular dopamine. The diagnosis relies on a characteristic pattern of biogenic amine metabolites exclusively in the CSF and can be confirmed by establishing a mutation in the TH gene. Here we present a patient meeting all diagnostic criteria, including a new homozygous mutation (926T>C) with confirmed parental heterozygosity, extrapyramidal symptoms, but atypical other symptoms with periodic neurological episodes observed every 4 days and unresponsive to dopa treatment. The CSF biochemical abnormalities were severe. Uncharacteristically, a strongly abnormal urinary catecholamine metabolite pattern was also consistently observed. The atypical presentation of this patient shows that the clinical and metabolic phenotype of TH deficiency is more variable than formerly thought, and that the condition should no longer be considered as a treatable disorder per se .